Xarelto Survey Scandal Calls into Question Bayer’s Organizational Setup, Employee Ethics

By Takashi Ebisawa A third-party probe into a scandal surrounding Xarelto (rivaroxaban) patient surveys wrapped up earlier this month, laying bare a series of problems inside Osaka-based Bayer Yakuhin, the Japan pharma unit Bayer AG. For one, there was a...read more